The U.S. Food and Drug Administration has approved Viridian Therapeutics' NASDAQ:VRDN drug to treat patients with thyroid eye disease, the company said on Friday.
Reuters
US FDA greenlights Viridian's eye disease drug
- Sources
- Reuters
- Markets
- Stocks
- Active symbols
- NASDAQ:VRDN
- Language
- English